LABORATORY MARKERS OF ABDOMINAL OBESITY AND METABOLIC SYNDROME PROGRESSION IN YOUNG ADULTS
DOI: 10.22138/2500-0918-2025-22-3-247-256
V.A. Sumerkina, L.F. Telesheva, E.S. Golovneva, D.E. Myakotina
South Ural State Medical University, Chelyabinsk, Russian Federation
Abstract: Isolated abdominal obesity (AO) and metabolic syndrome (MS) are increasingly associated with chronic low-intensity inflammation. In recent years, it has become known that immune disorders persist after weight loss. Obesity is associated with changes in the quantitative composition and functional activity of immune cells in adipose tissue, as well as the range of mediators they secrete. However, the issue of the primacy of immune dysfunction in MS is not considered in the scientific community. Determination of predictors of AO formation in healthy individuals, as well as predictors of AO transition to MS, is of great scientific interest and practical significance. The aim of the study was to determine laboratory markers of AO occurrence and its progression to MS in young individuals. Methods. 244 young patients (18-44 years old) with AO and MS were examined. The following groups of patients were formed: comparisons (conditionally healthy individuals, n=71); with isolated AO (n=32); with AO and 1 of the MS components (AO+1) (n=63); a group of patients with MS (n=78). Among the laboratory parameters, the most important predictors of OA and MS development were identified, based on which models were built for predicting the occurrence of AO and its progression to MS. Results. In practically healthy individuals, predictors of AO development are an increase in body mass index (BMI) and a decrease in IFNγ concentration, predictors of transition to the AO+1 stage are BMI, TFPI, IL-1β, IL-10, IFNγ. Laboratory markers of MS development: an increase in BMI, LDL-C, VAI, IFNγ and a decrease in IL-8. Conclusion. The initiating events in the development of MS are an increase in BMI and a decrease in the concentration of IFNγ. The development of MS from the early stages is closely associated with immune disorders, the severity of which increases as the disease progresses. This process is accompanied by an increase in the visceral adipose tissue dysfunction index (VAI), as well as changes in the levels of a number of indicators, such as BMI, LDL-C, TFPI, IL-1β, IL-8, IL-10, IFNγ.
Keywords: metabolic syndrome; abdominal obesity; markers of progression
There is no conflict of interest.
Contact details of the corresponding author:
Darya E. Myakotina
darya.myakotina16@mail.ru
Recieved 24.04.2025
For citation: Sumerkina V. A., Telesheva L.F., Golovneva E.S., Myakotina D. E. Laboratory markers of abdominal obesity and metabolic syndrome progression in young adults. [Online] Vestn. Ural. Med. Akad. Nauki. = Journal of Ural Medical Academic Science. 2025, Vol. 22, no. 3, pp. 247-256. DOI: 10.22138/2500-0918-2025-22-3-247-256 (In Russ)
REFERENCES
1. Guidelines on treatment of patients with arterial hypertension comorbid with metabolic disorders and diabetes mellitus type 2. Systemic Hypertension= Sistemnaya gipertenziya. 2020; Vol.17 No.1: 7–45, (InRuss.).
2. Sveklina T.S., Talantseva T.S., Barsukov A.V. Metabolic syndrome and inflammation: topical issues of pathogenesis. Clinical laboratory diagnostics=Klinicheskaya laboratornaya diagnostika. 2013. Vol.58, No. 358, No. 3. – pp. 7-10, (InRuss.).
3. Sumerkina V.А., Golovneva Е.S., Telesheva L.F. The role of disordered hemostasis and humoral immunity in the development of metabolic syndrome in young adults. Pathological Physiology and Experimental Therapy=Patologicheskaya Fiziologiya i Eksperimental`naya terapiya. 2023; 67(4): 36-46, (InRuss.).
4. Theodorakis N., Nikolaou M. From Cardiovascular-Kidney-Metabolic Syndrome to Cardiovascular-Renal-Hepatic-Metabolic Syndrome: Proposing an Expanded Framework. Biomolecules. 2025; Vol. 15(2). DOI: 10.3390/biom15020213.
5. Rohm T.V., Meier D.T., Olefsky J.M., Donath M.Y. Inflammation in obesity, diabetes, and related disorders. Immunity. 2022, Vol. 55(1), pp. 31-55. DOI: 10.1016/j.immuni.2021.12.013.
Auhtors
Veronika A. Sumerkina
Ph.D. of Medical Sciences, Leading Researcher, Head of the Central Research Laboratory
veronika.sumerkina@mail.ru
Larisa F. Telesheva
MD, professor of Department of Microbiology, Virology, Immunology
teleshevalarisa@mail.ru
Elena S. Golovneva
MD, professor of the Department of Normal Physiology named after Academician Yu.M. Zakharov
micron30@mail.ru
Darya E. Myakotina
Biologist at the Research Institute of Immunology
darya.myakotina16@mail.ru
South Ural State Medical University
Chelyabinsk, Russian Federation